AlphAIAlphAI — Financial news for AI agents
SEC EDGAR 8-KSEP 161 min read$SBFM

Sunshine Biopharma Inc. (SBFM): Submission of Matters to a Vote of Security Holders

Sunshine Biopharma Inc. (SBFM) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07 Submission of Matters to a Vote of Security Holders. On September 15, 2026, Dr. Steve N. Slilaty, as the holder of the majority of the voting power of the stockholders of Sunshine Biopharma Inc. (the “Company”), approved by written consent authorizing the Company’s boar

Original reporting
SEC EDGAR 8-K
Published Sep 16, 2026, 8:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 16, 2026, 8:15 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefCorporate actions
Primary signal
$SBFM
Neutral
medium confidence
Mentioned
$SBFM
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$SBFMNeutralMed
01

Why it matters

The reverse split consent is a primary corporate action that may affect share price and liquidity.

02

Market read

Primary disclosure of a corporate action for a micro‑cap; modest trading relevance.

03

What to watch

Potential dilution from future financing rounds post‑split.

Relevance 6/10Novelty 8/10Timing: filing date September 16, 2026

Background

Sunshine Biopharma is a micro‑cap biotech with majority ownership held by its CEO.

Company-level read

Ticker impact

$SBFMNeutralMedium confidence
Context

SEC 8‑K filing discloses shareholder consent for a potential 1‑for‑20 reverse stock split.

Expected impact

Potential short‑term price volatility with upside if market perceives reduced float positively.

Evidence & confidence

Corporate action is material for a micro‑cap; impact depends on execution and investor perception.

Market effects

Sector

May signal consolidation trend in biotech micro‑caps.

Regional

Limited to U.S. OTC market where SBFM trades.

Global

Low global relevance.

Counterpoint

What could challenge this read

Reverse split could be a precursor to delisting if company fails to meet exchange requirements.

Key entities

  • Company
    Sunshine Biopharma Inc.

    Biopharma company filing the 8‑K.

  • Executive
    Dr. Steve N. Slilaty

    CEO and majority shareholder approving the split.

Read at source← All news

Related articles

SEP 16
$SBFMMedAI 8/10

Sunshine Biopharma Inc.: Sunshine Biopharma Advances Lead Coronavirus Drug Candidate into IND-Enabling Studies

Sunshine Biopharma Inc. (NASDAQ: SBFM) announced its lead coronavirus drug candidate has entered IND-enabling studies. The company reported nanomolar potency against viral protease, broad-spectrum activity against SARS-CoV-2 variants, and strong oral bioavailability in multiple species. The drug also showed dose-dependent suppression of pulmonary viral replication in vivo. According to the company, the candidate is preferentially enriched in the lungs of mice and rats.

finanznachrichten.de2 min
SEP 16
$SBFMMedAI 8/10

Sunshine Biopharma Advances Lead Coronavirus Drug Candidate into IND-Enabling Studies

Sunshine Biopharma (NASDAQ:SBFM) announced its lead coronavirus drug candidate has entered IND-enabling studies. The drug showed nanomolar potency against viral protease, broad-spectrum activity against SARS-CoV-2 variants, and significant dose-dependent suppression of pulmonary viral replication in vivo. It also demonstrated strong oral bioavailability and preferential lung enrichment in multiple species.

accessnewswire.com2 min
SEP 16
$SBFMLow

An oral drug candidate suppressed lung virus in infected mice

Sunshine Biopharma (SBFM) advanced its lead coronavirus drug candidate into IND-enabling studies. The PLpro inhibitor showed nanomolar potency, broad in vitro activity against SARS-CoV-2 variants, and dose-dependent viral suppression in infected mice. The company reports high oral bioavailability and lung enrichment in multiple species. Sunshine Biopharma positions this as a differentiated antiviral program with scientific and commercial potential.

stocktitan.net2 min
AUG 26
$SBFMMedAI 8/10

Sunshine Biopharma Reports In Vivo Tumor Suppression with K1.1 mRNA and Advances Novel mRNA-Cancer Vaccine Strategy for Lung Cancer

Sunshine Biopharma (NASDAQ: SBFM) reported that its K1.1 mRNA therapy showed tumor-suppressing activity in liver cancer models. The company plans to combine it with a cancer vaccine to treat non-small cell lung cancer (NSCLC), aiming to convert 'cold' tumors into 'hot' tumors. The K1.1 mRNA targets a tumor suppressor frequently mutated in lung, pancreatic, and liver cancers.

accessnewswire.com2 min